SABS

SAB Biotherapeutics, Inc.

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$3.08

Price (1 Year)

$4.39 $2.53

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %3.4 / %30
Non-compliant assets / Total market cap %200.3 / %30
Non-compliant revenue / Total income %97.8 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials.

Website

Analysis (Turkish): SABS Hissesi Caiz mi, Helal mi? SAB Biotherapeutics, Inc. Katılım Analizi